141 related articles for article (PubMed ID: 32229654)
1. Peptidomic and proteomic analysis of stool for diagnosing IBD and deciphering disease pathogenesis.
Basso D; Padoan A; D'Incà R; Arrigoni G; Scapellato ML; Contran N; Franchin C; Lorenzon G; Mescoli C; Moz S; Bozzato D; Rugge M; Plebani M
Clin Chem Lab Med; 2020 Jun; 58(6):968-979. PubMed ID: 32229654
[TBL] [Abstract][Full Text] [Related]
2. Proteomic Analysis Identifies Three Reliable Biomarkers of Intestinal Inflammation in the Stools of Patients With Inflammatory Bowel Disease.
Vitali R; Palone F; Armuzzi A; Fulci V; Negroni A; Carissimi C; Cucchiara S; Stronati L
J Crohns Colitis; 2023 Jan; 17(1):92-102. PubMed ID: 36040453
[TBL] [Abstract][Full Text] [Related]
3. Low Mass Blood Peptides Discriminative of Inflammatory Bowel Disease (IBD) Severity: A Quantitative Proteomic Perspective.
Wasinger VC; Yau Y; Duo X; Zeng M; Campbell B; Shin S; Luber R; Redmond D; Leong RW
Mol Cell Proteomics; 2016 Jan; 15(1):256-65. PubMed ID: 26530476
[TBL] [Abstract][Full Text] [Related]
4. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
6. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
7. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
8. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
[TBL] [Abstract][Full Text] [Related]
9. Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease.
Thorsvik S; Damås JK; Granlund AV; Flo TH; Bergh K; Østvik AE; Sandvik AK
J Gastroenterol Hepatol; 2017 Jan; 32(1):128-135. PubMed ID: 27640344
[TBL] [Abstract][Full Text] [Related]
10. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease.
Kisiel JB; Yab TC; Nazer Hussain FT; Taylor WR; Garrity-Park MM; Sandborn WJ; Loftus EV; Wolff BG; Smyrk TC; Itzkowitz SH; Rubin DT; Zou H; Mahoney DW; Ahlquist DA
Aliment Pharmacol Ther; 2013 Mar; 37(5):546-54. PubMed ID: 23347191
[TBL] [Abstract][Full Text] [Related]
11. Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases.
Schönauen K; Le N; von Arnim U; Schulz C; Malfertheiner P; Link A
Inflamm Bowel Dis; 2018 Jun; 24(7):1547-1557. PubMed ID: 29668922
[TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease.
Walkiewicz D; Werlin SL; Fish D; Scanlon M; Hanaway P; Kugathasan S
Inflamm Bowel Dis; 2008 May; 14(5):669-73. PubMed ID: 18240279
[TBL] [Abstract][Full Text] [Related]
13. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
[TBL] [Abstract][Full Text] [Related]
14. Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability.
Padoan A; D'Incà R; Scapellato ML; De Bastiani R; Caccaro R; Mescoli C; Moz S; Bozzato D; Zambon CF; Lorenzon G; Rugge M; Plebani M; Basso D
Clin Chem Lab Med; 2018 Oct; 56(11):1926-1935. PubMed ID: 29729144
[TBL] [Abstract][Full Text] [Related]
15. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
[TBL] [Abstract][Full Text] [Related]
16. Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD.
De Preter V; Machiels K; Joossens M; Arijs I; Matthys C; Vermeire S; Rutgeerts P; Verbeke K
Gut; 2015 Mar; 64(3):447-58. PubMed ID: 24811995
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of a Patient-reported Score to Screen for Mucosal Inflammation in Inflammatory Bowel Disease.
de Jong MJ; Roosen D; Degens JHRJ; van den Heuvel TRA; Romberg-Camps M; Hameeteman W; Bodelier AGL; Romanko I; Lukas M; Winkens B; Markus T; Masclee AAM; van Tubergen A; Jonkers DMAE; Pierik MJ
J Crohns Colitis; 2019 Apr; 13(5):555-563. PubMed ID: 30476099
[TBL] [Abstract][Full Text] [Related]
18. Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease.
Dolinšek J; Rižnik P; Sabath L; Mičetić-Turk D
Wien Klin Wochenschr; 2016 Apr; 128(7-8):253-9. PubMed ID: 26659704
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases.
Farkas K; Saródi Z; Bálint A; Földesi I; Tiszlavicz L; Szűcs M; Nyári T; Tajti J; Nagy F; Szepes Z; Bor R; Annaházi A; Róka R; Molnár T
J Crohns Colitis; 2015 Mar; 9(3):231-7. PubMed ID: 25585596
[TBL] [Abstract][Full Text] [Related]
20. Fecal Amino Acid Analysis Can Discriminate De Novo Treatment-Naïve Pediatric Inflammatory Bowel Disease From Controls.
Bosch S; Struys EA; van Gaal N; Bakkali A; Jansen EW; Diederen K; Benninga MA; Mulder CJ; de Boer NKH; de Meij TGJ
J Pediatr Gastroenterol Nutr; 2018 May; 66(5):773-778. PubMed ID: 29112087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
